Concurrent Session 3A: From Evidence to Early Adoption: What will it take to deliver LADB access in LMICs
Tracks
.
| Thursday, October 8, 2026 |
| 11:15 AM - 12:15 PM |
| Zenit |
Details
Since INHSU 2025, global momentum around long-acting depot buprenorphine (LADB) in low- and middle-income countries (LMICs) has grown significantly. New implementation research findings, country readiness signals, and early market-shaping efforts are helping clarify what it will take to translate promise into practice.
This session will build directly on prior discussions at INHSU and include both foundational evidence and practical pathways for early introduction and scale. Speakers will share updated evidence, lessons from early adopter countries, community-led introduction, and progress on financing – including Global Fund Grant Cycle 8, regulatory, and market-enabling mechanisms. The session will also explore how global and national actors can work together to ensure equitable, sustainable access to LADB as a harm reduction and hepatitis prevention tool.
The aim is to move the conversation from why LADB matters to how access can realistically happen in LMICs.
Speaker
Dr Kimberly Green
Global Program Director, Primary Health Care
PATH
Opening remarks: Framing LADB as an additional choice for OAMT and recent WHO recommendation
11:15 AM - 11:20 AMBiography
Dr Kimberly Green
Global Program Director, Primary Health Care
PATH
Initial evidence from LADB studies in LMICs on acceptability, feasibility, effectiveness, cost-effectiveness
11:20 AM - 11:28 AMBiography
Dr Annie Madden
Project Lead
International Network of People Who Use Drugs (INPUD)
Initial evidence from LADB studies in LMICs on acceptability, feasibility, effectiveness, cost-effectiveness
11:20 AM - 11:28 AMBiography
Maria Phelan
Senior Technical Advisor: Key Populations
The Global Fund
Guidance on how countries can include LADB in Global Fund Funding Requests
11:28 AM - 11:36 AMBiography
Mr. Kanishk Gupta
Market Shaping Officer
PATH
Overview of pricing, regulatory and demand planning for LADB in LMICs
11:36 AM - 11:44 AMBiography
Market Shaping Officer at PATH and a product introduction and market access specialist with 15 years of experience. His current work focuses on expanding access to hepatitis and harm reduction products for people who inject drugs across low- and middle-income countries. He contributes to market assessments, demand forecasting, investment cases, manufacturer engagement, and introduction strategies for hepatitis C diagnostics and treatment, low dead space syringes and needles, and opioid agonist therapies, including long-acting injectable buprenorphine.
Dr Raghda Algamil
Director of Addiction Treatment Administration
Ministry of Health- General Secretariat of Mental Health and Addiction. , Egypt
Panel Discussion: What it takes to move from LADB pilots to programs: Country Ministry of Health, community, WHO and funders perspectives
11:44 AM - 12:10 PMBiography
Ms Victoria Goodfellow
Head Of Infectious Diseases
Medaccess
Panel Discussion: What it takes to move from LADB pilots to programs: Country Ministry of Health, community, WHO and funders perspectives
11:44 AM - 12:10 PMBiography
Victoria Goodfellow is a senior health financing expert with over two decades of experience across healthcare financing and investment banking. Victoria has focused largely on expanding access to essential health commodities in sub-Saharan Africa, through roles spanning system-level financing, innovative finance and the procurement of medicines and diagnostics for infectious diseases. At MedAccess, Victoria is Head of Infectious Diseases. She works with partners to identify opportunities where innovative finance can overcome barriers to accessing health innovations. Victoria holds a Master’s in International Health Policy (Health Economics) from the London School of Economics and a Bachelor of Economic Science from the University of Manchester.
Dr Dzmitry Krupchanka
Medical Officer
WHO
Panel Discussion: What it takes to move from LADB pilots to programs: Country Ministry of Health, community, WHO and funders perspectives
11:44 AM - 12:10 PMBiography
Dr Dzmitry Krupchanka is a Medical Officer at the Alcohol, Drugs and Addictive Behaviours Unit (ADA), Department of Mental Health, Brain Health and Substance Use (MSD) of the World Health Organization (WHO). In this role he is responsible for implementing a range of activities in prevention, treatment and care of disorders due substance use, addictive behaviours and related health conditions. This includes contribution to WHO normative guidance and technical support to countries, generation, and dissemination of evidence through international research projects, workforce development, monitoring and evaluation, enhancing joint efforts and advocacy in the area of alcohol, drugs and addictive behaviours. Dzmitry is a medical doctor and psychiatrist by professional background (Belarusian State Medical University, Belarus) with a MSc degree in Global Mental Health (University of London, UK) and PhDs in Clinical Psychiatry and Global Health (University of Geneva, Switzerland).
Abou Mere
Cab Member
HepC3P Global Community Advisory Board (CAB)
Panel Discussion: What it takes to move from LADB pilots to programs: Country Ministry of Health, community, WHO and funders perspectives
11:44 AM - 12:10 PMBiography
Dr Kingsley Michael
Assistant Director, Head of Harm Reduction and Hepatitis Component And Viral Hepatitis Component
National HIV/AIDS, Viral Hepatitis And STIs Control Programme, Federal Ministry of Health And Social Welfare (FMOHSW)
Panel Discussion: What it takes to move from LADB pilots to programs: Country Ministry of Health, community, WHO and funders perspectives
11:44 AM - 12:10 PMBiography
Ms Vielta Parkhomenko
Cab Member
HepC3P Global Community Advisory Board (CAB)
Panel Discussion: What it takes to move from LADB pilots to programs: Country Ministry of Health, community, WHO and funders perspectives
11:44 AM - 12:10 PMBiography
Ms Catherina Timmermans
Technical Manager, Strategy
Unitaid
Closing Remarks: Key insights and shared priorities toward increasing choice for OAMT in LMICs
12:10 PM - 12:15 PMBiography